Renowned industry veteran brings extensive drug discovery, development and strategic growth expertise
Oxford, 3 April 2025 – Dark Blue Therapeutics (“Dark Blue”), a discovery and development biotech company pioneering the next generation of precision oncology medicines, today announces the appointment of Edwin Moses as Chairman with immediate effect.
Alastair MacKinnon, CEO of Dark Blue Therapeutics, said: “Edwin joins Dark Blue at a key point in our transition to becoming a clinical stage company. His extensive knowledge of drug discovery and development, married with his track record in building and financing successful businesses, will be invaluable as we progress our lead program, an oral first in class MLLT 1/3 degrader, into the clinic. We look forward to working with him and benefiting from his highly relevant expertise, experience and stewardship.”
Edwin Moses added: “Dark Blue has progressed its lead program from target validation, through drug discovery and is now preparing for human clinical trials within a year. I am excited to join this strong team which is focused on delivering clinical data over the next 24 months in acute myeloid leukemia and also expanding the program to address solid tumors. Dark Blue’s unique drug discovery engine has enabled the creation of a pipeline of innovative programs and their pioneering precision medicine approach has the potential to transform the way in which unique academic insights can be translated into potential cancer medicines.”
Edwin Moses has more than 30 years of Board level experience as a serial entrepreneur and value creator in over 20 European life science companies. As CEO, he built, Oxford Asymmetry International plc and Ablynx NV, led successful IPOs on the LSE, EuroNext and NASDAQ, and raised over USD500 million in equity and debt financing. Edwin was responsible for the sales of both companies generating values of £316 million and USD4.8 billion respectively. At Ablynx, he oversaw the whole process from discovery to approval and preparation for the launch of Cablivi™ - a product designed to treat an ultra-rare hematological disease. Edwin is currently also Chairman of Avantium NV, LabGenius Ltd and NanoSyrinx Ltd.
